While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss ...

The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...

When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously ...

Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...

As the creator of the blockbuster weight-loss drug Zepbound, and the blockbuster type 2 diabetes drug Mounjaro, Eli Lilly (NYSE: LLY) is exposed to a tremendous amount of opportunity. The question ...